Objective: To discuss a new anticoagulant drug to be used to prevent Stroke in Atrial Fibrillation patients and Venous Tromboembolism. Participants had to read some preliminary material prior to their participation.
Markets
Methodology
1 PCT member
1 GP
1 or 2 secondary/ primary joint formularies members
1 or 2 regional HTA members
3 KOLs (2 in Stroke prevention in Atrial Fibrillation, 1 in Venous Tromboembolism treatment)